阿贝尔莫斯基科罗拉多糖和相关代谢物通过调节肠道微生物群和调节FXR/STAT3信号通路来改善结肠炎
Linhai He1, Kaidi Chen1, Zepeng Chen1
1The Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing 210029, PR China; No. 1 Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing 210023, PR China.
International journal of biological macromolecules
|August 2, 2024
概括
阿贝尔莫斯基科罗拉多糖 (ACP) 通过调节肠道微生物群和调节FXR/STAT3通路,显示出治疗性结肠炎 (UC) 的潜力. 这项研究表明,ACP是ACP.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 微生物学 微生物学
背景情况:
- 性结肠炎 (UC) 是一种慢性肠道炎症疾病,其原因尚不清楚.
- 阿贝尔莫斯基科罗拉多糖 (ACP) 具有已知的抗氧化和免疫调节性质.
- 之前没有研究过ACP对UC的治疗应用.
研究的目的:
- 评估Abelmoschi Corolla Polysaccharides (ACP) 在治疗性结肠炎 (UC) 的治疗疗效.
- 阐明ACP在UC中发挥治疗作用的基本机制.
主要方法:
- 使用德克斯硫酸盐 (DSS) 诱导的大肠炎小鼠模型来评估治疗效果.
- 用16SrRNA测序分析便样本,以评估肠道微生物群的变化.
- 血清样本经历了非向的代谢学,以确定关键代谢物.
- 实验中使用了Farnesoid X受体淘汰 (FXR-/-) 小鼠来研究受体参与.
主要成果:
- 在DSS诱导的大肠炎模型中,ACP治疗显著改善了UC症状.
- 经过ACP政府的重新编程,肠道失生症增加了 Bacteroides, Blautia 和 Parabacteroides 的数量.
- 经过ACP治疗,缩了血清中的7-二氧化醇酸 (7-KDA) 含量.
- 发现ACP和7-KDA向Farnesoid X受体 (FXR),阻断STAT3酸化并修复肠道屏障.
结论:
- 阿贝尔莫斯基科罗拉多糖 (ACP) 显示出对性结肠炎 (UC) 的显著治疗潜力.
- 通过调节肠道微生物群组成和丰富7-KDA.等特定微生物代谢物来发挥其作用.
- 治疗机制涉及Farnesoid X受体 (FXR) /STAT3信号通路,导致肠道屏障修复.
更多相关视频
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Drugs for Treatment of Ulcerative Colitis in IBD
133
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
133
Drugs for Treatment of Constipation-Predominant IBS
151
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
151
Drugs for Treatment of Diarrhea-Predominant IBS
156
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
156
Inflammatory Bowel Disease IV: Pharmacological Management
124
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
124
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
149
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
149


